In individuals suffering from T2DM, Omeprazole + Domperidone offers substantial mitigation from symptoms of acid peptic disease, such as appetite loss, abdominal pain, nausea, flatulence, irregular bowel movements, and epigastric burning.

A real-world retrospective study aimed to assess the safety and efficacy of using Omeprazole + Domperidone in patients diagnosed with type 2 diabetes mellitus (T2DM) to treat acid peptic disease.

The researchers conducted a review of electronic medical records, specifically focusing on patients diagnosed with T2DM and acid peptic disease who were undergoing treatment with the combination of Omeprazole and Domperidone.

The study evaluated the efficacy of the therapy by comparing the resolution of acid peptic disease symptoms at visit 5 (120 days following the baseline visit) with visit 1 (the initial visit). Safety was investigated by exploring the reported adverse events that occurred during the 120-day treatment period.

The study (PRoton-pump Inhibitor in patients with type 2 DiabEtes mellitus [PRIDE-2]) encompassed a total of 174 participants, with a mean age of 51.5±9.6 years. The majority of the volunteers were male, accounting for 59.8% of the total. A significant number of subjects experienced relief from various acid peptic disease symptoms at visit 5 compared to visit 1.

These symptoms included altered bowel movements (94.7%), loss of appetite (93.6%), flatulence (100.0%), nausea (89.5%), epigastric burning (68.7%), and abdominal pain (91.6%). No deleterious adverse events were witnessed during the study.

The combination of Omeprazole and Domperidone proved advantageous in alleviating symptoms for patients with diabetes and acid peptic disease. This therapy was well-tolerated, showing minimal occurrence of minor adverse effects.